BNP Paribas Asset Management
VRDN icon

BNP Paribas Asset Management’s Viridian Therapeutics VRDN Stock Holding History

BNP Paribas Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74M Buy
140,260
+139,364
+15,554% +$4.14M ﹤0.01% 1004
2025
Q4 		$28K Buy
896
+327
+57% +$8.97K ﹤0.01% 1845
2025
Q3 		$12K Sell
569
-111
-16% -$2K ﹤0.01% 1585
2025
Q2 		$10K Buy
+680
New +$9.23K ﹤0.01% 1792

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BNP Paribas Asset Management's VRDN Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Viridian Therapeutics (VRDN) stake by 15,554% in Q1 2026, buying an estimated $4.14M and bringing the position to 140,260 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

BNP Paribas Asset Management first reported a position in VRDN in Q2 2025 and has held it in 4 quarters since. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • BNP Paribas Asset Management held 140,260 shares of Viridian Therapeutics worth $2.74M as of Q1 2026.
  • BNP Paribas Asset Management bought 139,364 Viridian Therapeutics shares in Q1 2026, an estimated $4.14M.
  • Viridian Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1004 holding.
  • BNP Paribas Asset Management first reported a position in Viridian Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.